Simcere Pharma was granted SFDA approval for Iremod, an oral iguratimod drug classified as belonging to the category of Disease Modifying Anti-rheumatic Drugs (DMARDS). It will be indicated to treat active rheumatoid arthritis. Iremod, which was developed by Simcere, will be the first global iguratimod offering. Simcere expected SFDA approval of the drug as long ago as 2009. However, the drug inhibits COX-2, which may have complicated the regulatory process. More details....

Stock Symbol: (NYSE: SCR)     Share this with colleagues: